Pancreatic Cancer Research

ResearcherBeckman Research InstituteActive in the last 2 years

Kota Nakamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6256-4117; OpenAlex author ID A5045199542. Sources: OpenAlex.

Their work

Papers
25 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 5 papers · 2024: 6 papers · 2025: 2 papers

Papers 25

  1. Role of radiotherapy in surgical approaches to pancreatic cancer treatment: A narrative review. Co-author DOI 10.1002/ags3.70012↗
  2. An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer. First author DOI 10.1007/s00535-025-02260-w↗
  3. Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement. Co-author DOI 10.1002/ags3.12726↗
  4. Prognostic significance of creatine kinase in resected pancreatic cancer. Co-author DOI 10.1002/jhbp.12081↗
  5. Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites. Co-author DOI 10.1016/j.pan.2024.07.013↗
  6. Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.08.003↗
  7. Clinical significance and therapeutic implication of CD200 in pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.10.007↗
  8. Critical Role of Preoperative Hyperglycemia in Association with GFAT-1 Expression in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15985-4↗
  9. Significance of multiple tumor markers measurements in conversion surgery for unresectable locally advanced pancreatic cancer. First author DOI 10.1016/j.pan.2023.06.001↗
  10. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic du… Co-author DOI 10.1016/j.pan.2023.10.014↗
  11. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-022-02057-1↗
  12. Identification of Nectin Family Interactive Gene Panel and Stratification of Clinical Outcomes in Patients with Pancreatic Cancer. Co-author DOI 10.1097/xcs.0000000000000808↗
  13. Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report. Co-author DOI 10.1186/s40792-023-01720-w↗
  14. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Co-author DOI 10.1053/j.gastro.2022.06.090↗
  15. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  16. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33284↗
  17. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. Co-author DOI 10.1016/j.pan.2021.01.013↗
  18. Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.3390/jcm10040873↗
  19. Application of liquid biopsy for surgical management of pancreatic cancer. Last author DOI 10.1002/ags3.12317↗
  20. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. Co-author DOI 10.1053/j.gastro.2020.04.057↗
  21. Risk Factors for Late-Onset Gastrointestinal Hemorrhage After Pancreatoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s00268-018-4791-7↗
  22. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Ca… Co-author DOI 10.1007/s00268-018-4820-6↗
  23. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.05.461↗
  24. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2018-0900↗
  25. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-018-1709-7↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 24 shared papers, 2018–2025 · strength 3.87
  2. Minako Nagai · 21 shared papers, 2018–2025 · strength 3.49
  3. Satoshi Yasuda · 12 shared papers, 2023–2025 · strength 2.50
  4. Taichi Terai · 13 shared papers, 2021–2025 · strength 2.47
  5. Yuichiro Kohara · 11 shared papers, 2023–2025 · strength 2.18
  6. Satoshi Nishiwada · 14 shared papers, 2018–2025 · strength 1.86
  7. Takahiro Akahori · 12 shared papers, 2018–2024 · strength 1.41
  8. Kenji Nakagawa · 10 shared papers, 2018–2023 · strength 1.12
  9. Naoya Ikeda · 7 shared papers, 2018–2021 · strength 0.67
  10. Ajay Goel · 5 shared papers, 2020–2023 · strength 0.63
  11. Toshihiro Tanaka · 5 shared papers, 2018–2025 · strength 0.57
  12. Tadataka Takagi · 4 shared papers, 2019–2021 · strength 0.47
  13. Kensuke Yamamura · 3 shared papers, 2020–2023 · strength 0.40
  14. Suguru Yamada · 3 shared papers, 2022–2023 · strength 0.40
  15. Yasuhiro Kodera · 3 shared papers, 2022–2023 · strength 0.40
  16. Kimihiko Kichikawa · 4 shared papers, 2018–2019 · strength 0.34
  17. Tsutomu Fujii · 2 shared papers, 2022–2023 · strength 0.29
  18. In Woong Han · 2 shared papers, 2022 · strength 0.23
  19. Eunsung Jun · 2 shared papers, 2022 · strength 0.23
  20. Joon Oh Park · 2 shared papers, 2022 · strength 0.23
  21. Daniel D. Von Hoff · 2 shared papers, 2022 · strength 0.23
  22. Chiharu Uchiyama · 1 shared paper, 2024 · strength 0.21
  23. Shoichi Kinoshita · 1 shared paper, 2024 · strength 0.19
  24. Hideyuki Nishiofuku · 2 shared papers, 2019 · strength 0.18
  25. Yuki Imazu · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.